{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:14:56Z","timestamp":1770351296814,"version":"3.49.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Radiol"],"DOI":"10.1007\/s00247-024-05979-5","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T16:02:02Z","timestamp":1721664122000},"page":"1416-1427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cystic fibrosis hepatobiliary involvement: an update on imaging in diagnosis and monitoring"],"prefix":"10.1007","volume":"54","author":[{"given":"William","family":"Wood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Treiy","family":"Tinich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Schooler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7088-8530","authenticated-orcid":false,"given":"Meghana","family":"Sathe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"5979_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1042\/BJ20110672","volume":"438","author":"AE Gillen","year":"2011","unstructured":"Gillen AE, Gosalia N, Leir SH, Harris A (2011) MicroRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene. Biochem J 438:25\u201332","journal-title":"Biochem J"},{"key":"5979_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1126\/science.2570460","volume":"245","author":"B Kerem","year":"1989","unstructured":"Kerem B, Rommens JM, Buchanan JA et al (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073\u20131080","journal-title":"Science"},{"key":"5979_CR3","unstructured":"US CF Foundation JHU, The Hospital for Sick Children (2011) CFTR2. https:\/\/cftr2.org\/.\u00a0Accessed 1 Jan 2024"},{"key":"5979_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","volume":"56","author":"DH Andersen","year":"1938","unstructured":"Andersen DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child 56:344\u2013399","journal-title":"Am J Dis Child"},{"key":"5979_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","volume":"41","author":"M Corey","year":"1988","unstructured":"Corey M, McLaughlin FJ, Williams M, Levison H (1988) A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 41:583\u2013591","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 1","key":"5979_CR6","first-page":"S5","volume":"57","author":"KA McBennett","year":"2022","unstructured":"McBennett KA, Davis PB, Konstan MW (2022) Increasing life expectancy in cystic fibrosis: advances and challenges. Pediatr Pulmonol 57(Suppl 1):S5\u2013S12","journal-title":"Pediatr Pulmonol"},{"key":"5979_CR7","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco M (2019) CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 10:1662","journal-title":"Front Pharmacol"},{"key":"5979_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","volume":"4","author":"JC Davies","year":"2016","unstructured":"Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green Y, Cooke J, Rosenfeld M, Group KS (2016) Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med 4:107\u2013115","journal-title":"Lancet Respir Med"},{"key":"5979_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","volume":"6","author":"M Rosenfeld","year":"2018","unstructured":"Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC, group As (2018) Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med 6:545\u2013553","journal-title":"Lancet Respir Med"},{"key":"5979_CR10","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","volume":"377","author":"JL Taylor-Cousar","year":"2017","unstructured":"Taylor-Cousar JL, Munck A, McKone EF et al (2017) Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 377:2013\u20132023","journal-title":"N Engl J Med"},{"key":"5979_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP, Group TS, Group TS (2015) Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220\u2013231","journal-title":"N Engl J Med"},{"key":"5979_CR12","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS, Group VXT (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394:1940\u20131948","journal-title":"Lancet"},{"key":"5979_CR13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R, Group VXS (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381:1809\u20131819","journal-title":"N Engl J Med"},{"key":"5979_CR14","unstructured":"Administration USFaD (2023) TRIKAFTA\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf.\u00a0Accessed 1 Jan 2024"},{"key":"5979_CR15","doi-asserted-by":"crossref","unstructured":"Sellers ZM, Assis DN, Paranjape SM, Sathe M, Bodewes F, Bowen M, Cipolli M, Debray D, Green N, Hughan KS, Hunt WR, Leey J, Ling SC, Morelli G, Peckham D, Pettit RS, Philbrick A, Stoll J, Vavrina K, Allen S, Goodwin T, Hempstead SE, Narkewicz MR (2024) Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology 79:1220\u20131238","DOI":"10.1097\/HEP.0000000000000646"},{"key":"5979_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/MCP.0b013e3282f10a16","volume":"13","author":"C Colombo","year":"2007","unstructured":"Colombo C (2007) Liver disease in cystic fibrosis. Curr Opin Pulm Med 13:529\u2013536","journal-title":"Curr Opin Pulm Med"},{"issue":"62\u201369","key":"5979_CR17","first-page":"e64","volume":"219","author":"MJ Siegel","year":"2020","unstructured":"Siegel MJ, Freeman AJ, Ye W, Palermo JJ, Molleston JP, Paranjape SM, Stoll J, Leung DH, Masand P, Karmazyn B, Harned R, Ling SC, Navarro OM, Karnsakul W, Alazraki A, Schwarzenberg SJ, Seidel FG, Towbin A, Alonso EM, Nicholas JL, Murray KF, Otto RK, Sherker AH, Magee JC, Narkewicz MR, Network C (2020) Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease: interim results of a prospective observational case-controlled study. J Pediatr 219(62\u201369):e64","journal-title":"J Pediatr"},{"key":"5979_CR18","unstructured":"Magee J (2023) Prediction by ultrasound of the risk of hepatic cirrhosis in cystic fibrosis liver disease (V1). In: Repository NC (ed). https:\/\/repository.niddk.nih.gov\/studies\/cfld-push\/.\u00a0Accessed 1 June 2024"},{"key":"5979_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","volume":"12","author":"T Flass","year":"2013","unstructured":"Flass T, Narkewicz MR (2013) Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros 12:116\u2013124","journal-title":"J Cyst Fibros"},{"key":"5979_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/MPG.0000000000001822","volume":"66","author":"AL Gominon","year":"2018","unstructured":"Gominon AL, Frison E, Hiriart JB et al (2018) Assessment of liver disease progression in cystic fibrosis using transient elastography. J Pediatr Gastroenterol Nutr 66:455\u2013460","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5979_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jcf.2016.08.002","volume":"16","author":"SA Woodruff","year":"2017","unstructured":"Woodruff SA, Sontag MK, Accurso FJ et al (2017) Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. J Cyst Fibros 16:139\u2013145","journal-title":"J Cyst Fibros"},{"key":"5979_CR22","first-page":"136","volume":"9","author":"N Kobelska-Dubiel","year":"2014","unstructured":"Kobelska-Dubiel N, Klincewicz B, Cichy W (2014) Liver disease in cystic fibrosis. Prz Gastroenterol 9:136\u2013141","journal-title":"Prz Gastroenterol"},{"issue":"Suppl 2","key":"5979_CR23","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jcf.2017.07.002","volume":"16","author":"DH Leung","year":"2017","unstructured":"Leung DH, Narkewicz MR (2017) Cystic fibrosis-related cirrhosis. J Cyst Fibros 16(Suppl 2):S50\u2013S61","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"5979_CR24","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","volume":"10","author":"D Debray","year":"2011","unstructured":"Debray D, Kelly D, Houwen R et al (2011) Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 10(Suppl 2):S29-36","journal-title":"J Cyst Fibros"},{"key":"5979_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/hep.29217","volume":"66","author":"C Koh","year":"2017","unstructured":"Koh C, Sakiani S, Surana P et al (2017) Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity. Hepatology 66:591\u2013601","journal-title":"Hepatology"},{"key":"5979_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/MPG.0000000000003944","volume":"78","author":"F Bodewes","year":"2024","unstructured":"Bodewes F, Freeman AJ, Weymann A et al (2024) Towards a standardized classification of the hepatobiliary manifestations in cystic fibrosis (CFHBI): a joint ESPGHAN\/NASPGHAN position paper. J Pediatr Gastroenterol Nutr 78:153\u2013165","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5979_CR27","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/s41436-019-0449-6","volume":"21","author":"PY Boelle","year":"2019","unstructured":"Boelle PY, Debray D, Guillot L, Corvol H, French CFMGSI (2019) SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genet Med 21:2151\u20132155","journal-title":"Genet Med"},{"key":"5979_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/MPG.0000000000002413","volume":"69","author":"SC Ling","year":"2019","unstructured":"Ling SC, Ye W, Leung DH et al (2019) Liver ultrasound patterns in children with cystic fibrosis correlate with noninvasive tests of liver disease. J Pediatr Gastroenterol Nutr 69:351\u2013357","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5979_CR29","doi-asserted-by":"crossref","unstructured":"Siegel MJ, Leung DH, Molleston JP, Ye W, Paranjape SM, Freeman AJ, Palermo JJ, Stoll J, Masand P, Karmazyn B, Harned R, Ling SC, Navarro OM, Karnsakul W, Alazraki A, Schwarzenberg SJ, Towbin AJ, Alonso EM, Nicholas JL, Green N, Otto RK, Magee JC, Narkewicz MR (2023) Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease. J Cyst Fibros 22:745\u2013755","DOI":"10.1016\/j.jcf.2023.03.019"},{"key":"5979_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","volume":"76","author":"J Dana","year":"2022","unstructured":"Dana J, Debray D, Beaufrere A et al (2022) Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 76:420\u2013434","journal-title":"J Hepatol"},{"key":"5979_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.5009\/gnl16078","volume":"11","author":"H Maruyama","year":"2017","unstructured":"Maruyama H, Yokosuka O (2017) Ultrasonography for noninvasive assessment of portal hypertension. Gut Liver 11:464\u2013473","journal-title":"Gut Liver"},{"key":"5979_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jcf.2009.05.002","volume":"8","author":"DH O\u2019Donnell","year":"2009","unstructured":"O\u2019Donnell DH, Ryan R, Hayes B et al (2009) Hepatocellular carcinoma complicating cystic fibrosis related liver disease. J Cyst Fibros 8:288\u2013290","journal-title":"J Cyst Fibros"},{"key":"5979_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jcf.2023.03.019","volume":"22","author":"MJ Siegel","year":"2023","unstructured":"Siegel MJ, Leung DH, Molleston JP et al (2023) Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease. J Cyst Fibros 22:745\u2013755","journal-title":"J Cyst Fibros"},{"issue":"862\u2013868","key":"5979_CR34","doi-asserted-by":"publisher","first-page":"e862","DOI":"10.1016\/j.jpeds.2015.06.062","volume":"167","author":"DH Leung","year":"2015","unstructured":"Leung DH, Ye W, Molleston JP, Weymann A, Ling S, Paranjape SM, Romero R, Schwarzenberg SJ, Palermo J, Alonso EM, Murray KF, Marshall BC, Sherker AH, Siegel MJ, Krishnamurthy R, Harned R, Karmazyn B, Magee JC, Narkewicz MR, Disease CFL, N, (2015) Baseline ultrasound and clinical correlates in children with cystic fibrosis. J Pediatr 167(862\u2013868):e862","journal-title":"J Pediatr"},{"key":"5979_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MPG.0000000000002412","volume":"69","author":"ZM Sellers","year":"2019","unstructured":"Sellers ZM, Lee LW, Barth RA, Milla C (2019) New algorithm for the integration of ultrasound into cystic fibrosis liver disease screening. J Pediatr Gastroenterol Nutr 69:404\u2013410","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5979_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jcf.2022.07.017","volume":"22","author":"DH Leung","year":"2023","unstructured":"Leung DH, Ye W, Schwarzenberg SJ, Freeman AJ, Palermo JJ, Weymann A, Alonso EM, Karnsakul WW, Murray KF, Stoll JM, Huang S, Karmazyn B, Masand P, Magee JC, Alazraki AL, Towbin AJ, Nicholas JL, Green N, Otto RK, Siegel MJ, Ling SC, Navarro OM, Harned RK, Narkewicz MR, Molleston JP, Network CR (2023) Long-term follow-up and liver outcomes in children with cystic fibrosis and nodular liver on ultrasound in a multi-center study. J Cyst Fibros 22:248\u2013255","journal-title":"J Cyst Fibros"},{"key":"5979_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jcf.2007.08.001","volume":"7","author":"PR Mueller-Abt","year":"2008","unstructured":"Mueller-Abt PR, Frawley KJ, Greer RM, Lewindon PJ (2008) Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. J Cyst Fibros 7:215\u2013221","journal-title":"J Cyst Fibros"},{"key":"5979_CR38","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11894-014-0372-6","volume":"16","author":"A Bonder","year":"2014","unstructured":"Bonder A, Afdhal N (2014) Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep 16:372","journal-title":"Curr Gastroenterol Rep"},{"key":"5979_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jcf.2012.12.013","volume":"12","author":"M Friedrich-Rust","year":"2013","unstructured":"Friedrich-Rust M, Schlueter N, Smaczny C et al (2013) Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. J Cyst Fibros 12:431\u2013439","journal-title":"J Cyst Fibros"},{"key":"5979_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","volume":"13","author":"EB Tapper","year":"2015","unstructured":"Tapper EB, Castera L, Afdhal NH (2015) FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol 13:27\u201336","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5979_CR41","doi-asserted-by":"crossref","unstructured":"Oeda S, Tanaka K, Oshima A et al (2020) Diagnostic accuracy of FibroScan and factors affecting measurements. Diagnostics (Basel) 10:940","DOI":"10.3390\/diagnostics10110940"},{"key":"5979_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clinre.2011.08.001","volume":"36","author":"M Sasso","year":"2012","unstructured":"Sasso M, Miette V, Sandrin L, Beaugrand M (2012) The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 36:13\u201320","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"5979_CR43","first-page":"605","volume":"8","author":"NH Afdhal","year":"2012","unstructured":"Afdhal NH (2012) Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y) 8:605\u2013607","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"5979_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12887-019-1487-6","volume":"19","author":"J Zeng","year":"2019","unstructured":"Zeng J, Zhang X, Sun C et al (2019) Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years. Bmc Pediatr 19:129","journal-title":"Bmc Pediatr"},{"key":"5979_CR45","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/MPG.0000000000002320","volume":"68","author":"AB Mjelle","year":"2019","unstructured":"Mjelle AB, Mulabecirovic A, Havre RF et al (2019) Normal liver stiffness values in children: a comparison of three different elastography methods. J Pediatr Gastroenterol Nutr 68:706\u2013712","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5979_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/jcag\/gwy029","volume":"2","author":"S Lam","year":"2019","unstructured":"Lam S, Nettel-Aguirre A, Van Biervliet S et al (2019) Transient elastography in the evaluation of cystic fibrosis-associated liver disease: systematic review and meta-analysis. J Can Assoc Gastroenterol 2:71\u201380","journal-title":"J Can Assoc Gastroenterol"},{"key":"5979_CR47","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jcf.2009.08.001","volume":"8","author":"P Witters","year":"2009","unstructured":"Witters P, De Boeck K, Dupont L et al (2009) Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. J Cyst Fibros 8:392\u2013399","journal-title":"J Cyst Fibros"},{"key":"5979_CR48","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/MPG.0b013e31812e56ff","volume":"45","author":"V de Ledinghen","year":"2007","unstructured":"de Ledinghen V, Le Bail B, Rebouissoux L et al (2007) Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 45:443\u2013450","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5979_CR49","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.21037\/tp-21-68","volume":"10","author":"A Tosco","year":"2021","unstructured":"Tosco A, Sepe A, Castaldo A et al (2021) Non-invasive tools for detection of liver disease in children and adolescents with cystic fibrosis. Transl Pediatr 10:2952\u20132959","journal-title":"Transl Pediatr"},{"key":"5979_CR50","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/hep4.1719","volume":"5","author":"W Ye","year":"2021","unstructured":"Ye W, Leung DH, Molleston JP et al (2021) Association between transient elastography and controlled attenuated parameter and liver ultrasound in children with cystic fibrosis. Hepatol Commun 5:1362\u20131372","journal-title":"Hepatol Commun"},{"key":"5979_CR51","doi-asserted-by":"publisher","first-page":"e0178784","DOI":"10.1371\/journal.pone.0178784","volume":"12","author":"V Klotter","year":"2017","unstructured":"Klotter V, Gunchick C, Siemers E et al (2017) Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: results from a prospective longitudinal cohort study. PLoS ONE 12:e0178784","journal-title":"PLoS ONE"},{"key":"5979_CR52","doi-asserted-by":"publisher","first-page":"4798136","DOI":"10.1155\/2022\/4798136","volume":"2022","author":"S Wiecek","year":"2022","unstructured":"Wiecek S, Fabrowicz P, Wos H et al (2022) Assessment of liver fibrosis with the use of elastography in paediatric patients with diagnosed cystic fibrosis. Dis Markers 2022:4798136","journal-title":"Dis Markers"},{"key":"5979_CR53","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00247-009-1531-z","volume":"40","author":"R Menten","year":"2010","unstructured":"Menten R, Leonard A, Clapuyt P et al (2010) Transient elastography in patients with cystic fibrosis. Pediatr Radiol 40:1231\u20131235","journal-title":"Pediatr Radiol"},{"key":"5979_CR54","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/liv.12113","volume":"33","author":"MT Kitson","year":"2013","unstructured":"Kitson MT, Kemp WW, Iser DM et al (2013) Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease. Liver Int 33:698\u2013705","journal-title":"Liver Int"},{"key":"5979_CR55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/MPG.0000000000001448","volume":"64","author":"A Aqul","year":"2017","unstructured":"Aqul A, Jonas MM, Harney S et al (2017) Correlation of transient elastography with severity of cystic fibrosis-related liver disease. J Pediatr Gastroenterol Nutr 64:505\u2013511","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5979_CR56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2174\/1574886317666220513105114","volume":"18","author":"A Kanavaki","year":"2023","unstructured":"Kanavaki A, Kanavaki I, Zoumpoulis PS et al (2023) Changes in shear wave elastography after lumacaftor\/ivacaftor treatment in children with cystic fibrosis. Curr Drug Saf 18:93\u201396","journal-title":"Curr Drug Saf"},{"key":"5979_CR57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/jpc.15741","volume":"58","author":"S Yavuz","year":"2022","unstructured":"Yavuz S, Piskin FC, Oktay C, Tumgor G (2022) Assessment of hepatic involvement by two-dimensional shear wave elastography in paediatric patients with cystic fibrosis. J Paediatr Child Health 58:459\u2013462","journal-title":"J Paediatr Child Health"},{"key":"5979_CR58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1148\/radiol.2020192437","volume":"296","author":"RG Barr","year":"2020","unstructured":"Barr RG, Wilson SR, Rubens D et al (2020) Update to the society of radiologists in ultrasound liver elastography consensus statement. Radiology 296:263\u2013274","journal-title":"Radiology"},{"key":"5979_CR59","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00330-019-06478-0","volume":"30","author":"R Rezvani Habibabadi","year":"2020","unstructured":"Rezvani Habibabadi R, Khoshpouri P, Ghadimi M et al (2020) Comparison between ROI-based and volumetric measurements in quantifying heterogeneity of liver stiffness using MR elastography. Eur Radiol 30:1609\u20131615","journal-title":"Eur Radiol"},{"key":"5979_CR60","doi-asserted-by":"crossref","unstructured":"Towbin AJ, Ye W, Huang S, Karmazyn BW, Molleston JP, Masand P, Leung DH, Chang S, Narkewicz MR, Alazraki AL, Freeman AJ, Otto RK, Green N, Kamel IR, Karnsakul WW, Magee JC, Tkach J, Palermo JJ (2023) Prospective study of quantitative liver MRI in cystic fibrosis: feasibility and comparison to PUSH cohort ultrasound. Pediatr Radiol 53:2210\u20132220","DOI":"10.1007\/s00247-023-05706-6"},{"key":"5979_CR61","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jhep.2004.10.002","volume":"41","author":"C Colombo","year":"2004","unstructured":"Colombo C, Battezzati PM (2004) Liver involvement in cystic fibrosis: primary organ damage or innocent bystander? J Hepatol 41:1041\u20131044","journal-title":"J Hepatol"},{"key":"5979_CR62","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.bpg.2010.08.003","volume":"24","author":"U Herrmann","year":"2010","unstructured":"Herrmann U, Dockter G, Lammert F (2010) Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol 24:585\u2013592","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"5979_CR63","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.4254\/wjh.v13.i11.1727","volume":"13","author":"JJ Valamparampil","year":"2021","unstructured":"Valamparampil JJ, Gupte GL (2021) Cystic fibrosis associated liver disease in children. World J Hepatol 13:1727\u20131742","journal-title":"World J Hepatol"},{"key":"5979_CR64","first-page":"340","volume":"2","author":"V Diwakar","year":"2001","unstructured":"Diwakar V, Pearson L, Beath S (2001) Liver disease in children with cystic fibrosis. Paediatr Respir Rev 2:340\u2013349","journal-title":"Paediatr Respir Rev"},{"key":"5979_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejrad.2006.11.008","volume":"61","author":"D Akata","year":"2007","unstructured":"Akata D, Akhan O (2007) Liver manifestations of cystic fibrosis. Eur J Radiol 61:11\u201317","journal-title":"Eur J Radiol"},{"key":"5979_CR66","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1148\/rg.2015140110","volume":"35","author":"LP Lavelle","year":"2015","unstructured":"Lavelle LP, McEvoy SH, Ni Mhurchu E et al (2015) Cystic fibrosis below the diaphragm: abdominal findings in adult patients. Radiographics 35:680\u2013695","journal-title":"Radiographics"},{"key":"5979_CR67","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1148\/radiographics.20.3.g00ma08767","volume":"20","author":"LJ King","year":"2000","unstructured":"King LJ, Scurr ED, Murugan N et al (2000) Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances. Radiographics 20:767\u2013777","journal-title":"Radiographics"},{"key":"5979_CR68","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41374-020-0474-8","volume":"100","author":"K Zarei","year":"2020","unstructured":"Zarei K, Stroik MR, Gansemer ND et al (2020) Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model. Lab Invest 100:1388\u20131399","journal-title":"Lab Invest"},{"key":"5979_CR69","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcf.2004.04.006","volume":"3","author":"D McKeon","year":"2004","unstructured":"McKeon D, Day A, Parmar J et al (2004) Hepatocellular carcinoma in association with cirrhosis in a patient with cystic fibrosis. J Cyst Fibros 3:193\u2013195","journal-title":"J Cyst Fibros"},{"key":"5979_CR70","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1097\/00042737-200510000-00018","volume":"17","author":"T Kelleher","year":"2005","unstructured":"Kelleher T, Staunton M, O\u2019Mahony S, McCormick PA (2005) Advanced hepatocellular carcinoma associated with cystic fibrosis. Eur J Gastroenterol Hepatol 17:1123\u20131124","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5979_CR71","unstructured":"Radiology ACo Liver Imaging Reporting & Data System (LI-RADS\u00ae). https:\/\/www.acr.org\/Clinical-Resources\/Reporting-and-Data-Systems\/LI-RADS.\u00a0Accessed 1 June 2024"},{"key":"5979_CR72","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1148\/radiol.2021203559","volume":"299","author":"G Khanna","year":"2021","unstructured":"Khanna G, Chavhan GB, Schooler GR et al (2021) Diagnostic performance of LI-RADS version 2018 for evaluation of pediatric hepatocellular carcinoma. Radiology 299:190\u2013199","journal-title":"Radiology"},{"key":"5979_CR73","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816\u2013830","journal-title":"Radiology"},{"key":"5979_CR74","doi-asserted-by":"crossref","unstructured":"Bass R, Brownell JN, Stallings VA (2021) The impact of highly effective CFTR modulators on growth and nutrition status. Nutrients 13:2907","DOI":"10.3390\/nu13092907"},{"key":"5979_CR75","doi-asserted-by":"publisher","first-page":"1157459","DOI":"10.3389\/fphar.2023.1157459","volume":"14","author":"M Mouzaki","year":"2023","unstructured":"Mouzaki M, Dupuis A, Avolio J et al (2023) Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass. Front Pharmacol 14:1157459","journal-title":"Front Pharmacol"},{"key":"5979_CR76","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","volume":"10","author":"Q Li","year":"2018","unstructured":"Li Q, Dhyani M, Grajo JR et al (2018) Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol 10:530\u2013542","journal-title":"World J Hepatol"},{"key":"5979_CR77","doi-asserted-by":"crossref","unstructured":"Soto A, Spongberg C, Martinino A, Giovinazzo F (2024) Exploring the multifaceted landscape of MASLD: a comprehensive synthesis of recent studies, from pathophysiology to organoids and beyond. Biomedicines 12:397","DOI":"10.3390\/biomedicines12020397"},{"key":"5979_CR78","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jcf.2017.03.006","volume":"16","author":"P Witters","year":"2017","unstructured":"Witters P, Libbrecht L, Roskams T et al (2017) Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. J Cyst Fibros 16:e11\u2013e13","journal-title":"J Cyst Fibros"},{"key":"5979_CR79","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/lt.24842","volume":"23","author":"S Hillaire","year":"2017","unstructured":"Hillaire S, Cazals-Hatem D, Bruno O et al (2017) Liver transplantation in adult cystic fibrosis: clinical, imaging, and pathological evidence of obliterative portal venopathy. Liver Transpl 23:1342\u20131347","journal-title":"Liver Transpl"},{"key":"5979_CR80","doi-asserted-by":"publisher","first-page":"20140653","DOI":"10.1259\/bjr.20140653","volume":"88","author":"A Arora","year":"2015","unstructured":"Arora A, Sarin SK (2015) Multimodality imaging of obliterative portal venopathy: what every radiologist should know. Br J Radiol 88:20140653","journal-title":"Br J Radiol"},{"key":"5979_CR81","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.cgh.2018.10.046","volume":"17","author":"H Wu","year":"2019","unstructured":"Wu H, Vu M, Dhingra S et al (2019) Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension. Clin Gastroenterol Hepatol 17:2134\u20132136","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5979_CR82","first-page":"289","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Coop Study Group Hepatol 24:289\u2013293","journal-title":"The METAVIR Coop Study Group Hepatol"},{"key":"5979_CR83","unstructured":"Cystic Fibrosis Foundation (2017) Know Your CFTR Mutations Infographic. https:\/\/www.cff.org\/sites\/default\/files\/2021-12\/Know-Your-CFTR-Mutations-Infographic.pdf.\u00a0Accessed 1 Jan 2024"}],"container-title":["Pediatric Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-024-05979-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00247-024-05979-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-024-05979-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T02:02:03Z","timestamp":1723687323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00247-024-05979-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":83,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["5979"],"URL":"https:\/\/doi.org\/10.1007\/s00247-024-05979-5","relation":{},"ISSN":["1432-1998"],"issn-type":[{"value":"1432-1998","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Meghana Sathe, MD has funding through the Cystic Fibrosis Foundation\u00a0and Anagram Therpeutics, Inc. No other conflicts of interest are reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}